SUSPECTED COVID-19 INFECTION; REVACCINATION WITH DIFFERENT COVID-19 VACCINE; This spontaneous report received from a patient via other company (Pfizer Inc.) concerned a 50 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: scleroderma, gastroesophageal reflux disease (GERD), and allergy, and other pre-existing medical conditions included: The patient was not pregnant at the time of vaccination and had no history of past drug. The patient stated she was taking other medication or products within 2 weeks of starting covid-19 treatment (Paxlovid). The patient received first dose with covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin not reported, batch number: 041A21A expiry: UNKNOWN) dose was not reported,1 total was administered on 07-APR-2021 to left arm for covid-19 prophylaxis. Age at time of vaccination 49 years old. Concomitant medications included amlodipine, hydroxychloroquine, and xantofyl (Lutein). It was unknown whether patient had any adverse events following vaccination with covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient additionally received 2 doses (second and third dose) with non-company suspect vaccine Moderna covid-19 vaccine, (elasomeran),(Dose number in series 2), (batch number: 066F21A expiry: UNKNOWN, form of admin, route of admin were not reported) dose was not reported, administered on 06-NOV-2021 to left arm, and (batch number: 065F21A expiry: UNKNOWN, form of admin, route of admin, and were not reported) dose was not reported, administered on 03-DEC-2021 to left arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with 2 doses of Moderna covid-19 vaccine (elasomeran) (Dose number in series 2). The patient also received fourth dose with non-company suspect vaccine Pfizer biontech covid-19 vaccine (tozinameran) (Dose number in series 3) (form of admin, route of admin, and were not reported, batch number: FM7553 expiry: UNKNOWN) dose was not reported, administered on 26-MAY-2022 to left arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with Pfizer biontech covid-19 vaccine (tozinameran) (Dose number in series 3). The patient also received fifth dose with non-company suspect vaccine Pfizer biontech covid-19 vaccine (tozinameran) (Dose number in series 4) (form of admin, route of admin, and batch number were not reported) dose was not reported, administered on 22-SEP-2022 for covid-19 prophylaxis which was associated with revaccination with different covid-19 vaccine (Dose number in series 4).  On an unspecified date, the patient experienced suspected covid-19 infection (Dose number in series 4). The patient started taking treatment with non-company suspect drug Paxlovid (nirmatrelvir/ritonavir) (form of admin, route of admin, batch number and expiry date were not reported) dose and frequency were not reported from 17-APR-2023 to 22-APR-2023 for treatment of covid-19.  On 23-APR-2023, (6 days after first dose of treatment with Paxlovid) and on 25-APR-2023 (8 days after first dose of treatment with Paxlovid), the patient was tested negative for rapid tests (COVID-19 rapid POC tests).  On 28-APR-2023, (11 days after first dose of treatment with Paxlovid), symptoms had returned again (covid-19 rebound infection). The action taken with covid-19 vaccine ad26.cov2.s, elasomeran, tozinameran, and tozinameran was not applicable; and action taken with nirmatrelvir/ritonavir was not reported. The outcome of the suspected covid-19 infection and revaccination with different covid-19 vaccine was not reported. This report was non-serious.